|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00002520 |
Purpose
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
PURPOSE: Randomized clinical trial to compare the effectiveness of a physician-initiated stop-smoking program with the usual care for patients receiving treatment for early-stage cancer.
| Condition | Intervention |
|
Bladder Cancer Breast Cancer Cancer-Related Problem/Condition Colorectal Cancer Head and Neck Cancer Lung Cancer Lymphoma Prostate Cancer Testicular Germ Cell Tumor Unspecified Adult Solid Tumor, Protocol Specific |
Drug: nicotine |
| Genetics Home Reference related topics: | bladder cancer breast cancer |
| Drug Information available for: | Nicotine polacrilex Nicotine tartrate Salicylsalicylic acid Sodium salicylate |
| Study Type: | Interventional |
| Study Design: | Other, Randomized, Active Control |
| Official Title: | Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings |
| Study Start Date: | June 1992 |
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center. Patients are randomized to 1 of 2 treatment arms.
All patients are followed at 6 and 12 months. Patients who report that they are still smoking and interested in help to quit smoking at the 12-month follow-up interview are encouraged to return to their physicians and contact the CIS for additional help quitting or for a referral to more intensive or specialized treatments in their area.
PROJECTED ACCRUAL: A total of 494 patients will be accrued for this study.
Eligibility
| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
One of the following diagnoses:
Hormone receptor status:
PATIENT CHARACTERISTICS:
Age:
Sex:
Menopausal status:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Contacts and Locations| United States, Pennsylvania | |||||
| Fox Chase Cancer Center | |||||
| Philadelphia, Pennsylvania, United States, 19111 | |||||
| Eastern Cooperative Oncology Group |
| National Cancer Institute (NCI) |
| Study Chair: | Paul F. Engstrom, MD | Fox Chase Cancer Center |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
| Study ID Numbers: | CDR0000078281, E-1Y92, NCI-P93-0042 |
| First Received: | November 1, 1999 |
| Last Updated: | October 18, 2008 |
| ClinicalTrials.gov Identifier: | NCT00002520 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|